分類: ACN Newswire

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 領先電子產品生產商華訊股份有限公司（「華訊」或「集團」）（股份代號：833）宣佈其位於馬來西亞檳城的生產基地正式啟用。該新設施為集團多元製造佈局策略的重要里程碑，標誌著拓展中國內地以外產能，並進一步強化東南亞的生產網絡。該檳城廠佔地約60,000平方呎，設有12條生產線，每月產能達250,000至300,000件。該廠作為原始設備製造（OEM）生產基地，主要生產銷往國際市場的工業電子產品、環境控制設備及電子電源模組。新增產能不僅擴大集團的整體製造規模，亦滿足持續增長的市場需求，為未來業務拓展提供穩固基礎。是次啟用乃承接集團於2025年完成的多項策略性部署，包括收購位於馬來西亞檳城及越南胡志明市的製造業務。進軍馬來西亞為集團首次在中國內地以外建立生產據點。集團於2025年8月完成收購檳城廠後，展開擴建及升級，引入先進設備及優化生產流程，以提升效率及品質管理水平。該設施現時生產灌溉感應器、恆溫器、保安設備及鋰電池組。華訊主席兼執行董事林賢奇先生表示：「檳城廠在推動集團建立更多元化製造網絡的策略中發揮關鍵作用。配合越南業務的拓展，我們正持續強化生產能力，提升整體供應鏈的靈活性，有助進一步增強集團的韌性與應變能力，使我們能在瞬息萬變的全球環境下更有效支援客戶業務發展。」華訊行政總裁兼執行董事林子泰先生補充指：「檳城廠正穩步提升產能，並已承接現有及新客戶的新增訂單。隨著生產線擴充及系統升級完成，產能將更趨充裕，以配合未來需求。集團亦正評估於馬來西亞設立另一個具相若產能的生產基地，推動下一階段的業務增長。」 馬來西亞官方代表、華訊董事局成員及管理層於當地新廠房舉行剪綵儀式。 華訊馬來西亞生產基地配備12條生產線，每月產能達250,000至300,000件，進一步擴大集團製造規模，滿足持續增長的客戶需求。有關華訊股份有限公司（股份代號：833）華訊股份有限公司主要從事設計及生產多款高質量且時尚的電子產品。本公司為明晟（「MSCI」）香港微型指數成份股。有關詳情，請瀏覽網頁http://www.alltronics.com.hk/。  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 君聖泰醫藥（股票代碼：2511.HK），一家專注於心腎代謝系統疾病（CKM）、開發多功能多靶點療法的創新生物醫藥公司，今日在英國格拉斯哥舉行的第63屆歐洲腎臟協會（ERA）年會上，以口頭報告的形式公佈了其核心產品HTD1801的腎臟保護最新研究結果。HTD1801是全球首創的靶向AMPK-NLRP3通路的抗炎代謝調節劑（AIMM）。在已完成的III期臨床研究（SYMPHONY-1&2）中，HTD1801顯著改善了基線eGFR為60–90 mL/min/1.73m²的2型糖尿病（T2DM）患者的腎功能。治療52周後，這些患者的eGFR平均升高了+3.08 mL/min/1.73m²（95% CI: 0.46–5.70），且未出現高濾過或體液瀦留。這些結果提示，HTD1801和現有機制藥物有差異化優勢，並具有延緩甚至逆轉疾病進程的潛力。本項研究進一步解釋了上述臨床結果。該研究由君聖泰醫藥與中國醫學科學院醫藥生物技術研究所蔣建東院士研究團隊共同完成，結果顯示，在葡萄糖及棕櫚酸誘導的足細胞損傷模型中，HTD1801可顯著提升足細胞存活率、抑制細胞凋亡；恢復足細胞關鍵結構蛋白nephrin與podocin的表達；並顯著降低代謝性炎症通路中磷酸化NF-κB及凋亡執行蛋白caspase-3水平。在糖尿病腎病（DN）模型中，HTD1801可呈劑量依賴性改善腎臟組織結構，降低腎小管損傷評分，減輕腎臟炎症及纖維化病變，並顯著降低24小時尿微量白蛋白水平。該研究系統性闡明HTD1801可抑制足細胞炎症與凋亡、穩定腎小球結構，進一步揭示了HTD1801的腎臟保護潛力，為其成為慢性腎病（CKD）及其他腎臟疾病的潛在療法提供了重要的科學依據。摘要標題：HTD1801減輕足細胞凋亡與腎小球損傷--腎臟保護機理探析報告編號：2243報告時間：2026年6月4日，星期四，上午8:15（英國夏令時間）報告形式：口頭報告報告人：Filip Surmont博士，君聖泰醫藥首席醫學官君聖泰醫藥首席醫學官Filip Surmont博士表示："此次研究首次從足細胞與腎小球層面揭示了HTD1801的腎臟保護作用。臨床研究與臨床前研究結果的高度一致，進一步證實了HTD1801在CKD或其他腎臟疾病中直擊核心病理進程的能力，彰顯了其重要治療潛力。我們將持續推進HTD1801在CKD等適應症的臨床開發，力求為全球腎病患者帶來更多創新的治療選擇。"關於HTD1801HTD1801是一款全球首創的新分子實體，旨在解決心腎代謝系統疾病（CKM）的未滿足臨床需求。HTD1801作為單一分子，是具有獨特雙機制的口服抗炎及代謝調節劑（AIMM），通過激活AMPK及抑制NLRP3炎症小體發揮其生物學活性；這種互補協同的雙機制作用可有效解決代謝問題。全球多項臨床結果驗證HTD1801具有"一藥多效"的特性，能夠為患者帶來綜合獲益，包括改善胰島素敏感性、血糖控制、血脂降低、腎臟保護、體重減輕、肝臟獲益及抗炎等。基於此，HTD1801有潛力成為CKM領域的基礎性治療藥物。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m².  Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves.                                 ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亞太商訊 via SeaPRwire.com) - 6月4日，Synology 群暉科技於 COMPUTEX 2026 盛大展出全新技術，現場更首度亮相創新的 AI 解決方案。本次參展涵蓋新一代 DiskStation Manager（DSM）作業系統、全新 ActiveProtect 備份專用一體機、完整的影像監控生態系、大幅升級的 Synology Office 套件，以及專為個人與家庭設計的 Bee Series 私有雲產品線。「資料是我們打造一切的核心，而信任則是穩固的基石。」Synology 董事長暨執行長翁英暉表示：「從企業基礎架構到個人雲端解決方案，我們研發的每款產品，都賦予使用者對資料的絕對主權。在毫不妥協的資安防護、可靠性與隱私保障之下，協助使用者充滿信心迎向未來的挑戰。」 更加智慧的 DSM 作業系統新一代 DSM 專為 AI 及企業需求而生，系統全面支援 GPU NAS 與 AI 硬體裝置，能落實全地端的 AI 推論與治理架構；而預計推出的 DSM Agent 則能橫跨系統，提供管理建議與設計自動化的工作流程。針對企業大規模部署需求，Cluster Manager 可整合多台系統至單一管理介面，並提供工作負載轉移、服務品質（QoS）控管與集中化保護機制；雲端監控平台 Active Insight 新增大規模部署功能，可快速部署多據點架構；最後全新升級的日誌中心，則能對接企業級可觀測性（Observability）平台，進一步強化資安防護與法規合規性。提升保護能力的 ActiveProtect Manager 2.0ActiveProtect Manager（APM） 2.0 擴大保護範圍，延伸至 AWS EC2、Azure VM、Proxmox、Nutanix AHV 與 Google Workspace，並支援跨平台還原，協助企業在混合雲與虛擬環境中保持資安韌性。本次還加入主動式威脅防禦，整合了 AI 驅動的異常與惡意程式偵測機制。同時，ActiveProtect 產品線迎來最新機種 DP5200 ，為企業帶來更高彈性的部署選擇。全新影像監控門禁控制、DVA 伺服器與混合雲監控Synology 影像監控生態系持續茁壯，首先展出門禁控制解決方案，包含 AC100 門禁控制器與 AR 系列讀卡機，並公開即將推出的 DC 系列半球型攝影機。再來智慧影像分析伺服器 DVA 系列導入了 AI 語意搜尋，與人員重識別（Re-identification）路徑追蹤等功能，有效提升監控效率。為使生態系更臻完善，Surveillance365 主打雲端監控服務（VSaaS），並能無縫整合地端的 Surveillance Station，為企業打造專屬的混合雲平台，完美實現遠端與多據點的安全監控。ChatPlus 與 Meet 強化溝通效率Synology Office Suite 正式增添生力軍 ChatPlus 與 Meet，為企業帶來具備細緻權限與管控功能的企業級通訊工具。兩款套件皆內建 AI 驅動的語音轉文字與翻譯功能，大幅提升團隊的協作效率，並確保所有資料完全落地、由企業 100% 掌控手中。專為個人與家庭打造的 Bee Series 私有雲生態系BeeStation與BeeStation Plus產品線，現在提供更豐富的容量與規格選擇，滿足多元的儲存需求。另外，使用者現在可透過BeeCamera功能，搭配Synology Cameras在BeeStation Plus上輕鬆展開監控；而基於macOS與Windows系統的 Synology Deep Search服務，則利用AI技術，提供高效的地端搜尋體驗，讓使用者在兼顧隱私的前提之下，精準找出個人裝置中的任何內容。欲了解更多Synology群暉科技產品和解決方案詳情或有任何需求， 歡迎至Synology群暉科技官網或聯繫 hk.event@synology.comMedia Contacts :Contact Us: https://www.synology.com/zh-hk/company/contact_us Synology Marketing & PR Specialist, Sandra Soh : sandrasoh@synology.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Zhangjiakou, China, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - In the first half of 2026, SnowValley, China's leading frozen potato product manufacturer, showcased its products and solutions at 4 of the world's premier food industry events — Gulfood in the Middle East, FOODEX Japan, FHA Food & Beverage in Singapore, and THAIFEX-Anuga Asia in Thailand. Through its presence at these flagship exhibitions, SnowValley further strengthened its reach across key consumer markets in the Middle East, East Asia, and Southeast Asia.Leveraging these world's top food industry exhibitions, SnowValley showcased its integrated industrial chain competitiveness and global service capabilities, attracting widespread attention from industry professionals, international buyers, and leading media worldwide.Recognized for multiple consecutive years among the Top 500 Chinese Brands and Top 500 Asian Brands, SnowValley continues to strengthen its international brand presence through its localized market strategies and deep engagement with overseas distribution networks across multiple countries. By securing a series of cross-border strategic partnerships, the company is further expanding its worldwide network and reinforcing its position in the global frozen potato products industry.Throughout the exhibitions, SnowValley earned strong recognition and trust from global buyers by leveraging its highly standardized manufacturing system, market-driven product customization capabilities, and efficient & reliable global supply chain. Today, SnowValley offers a portfolio of more than 160 SKUs, with products exported to over 40 countries and regions worldwide.With years of dedication to the potato products industry, SnowValley has achieved an all-round internationalization upgrade spanning product exports, brand development, and industry-standard promotion, driven by quality and innovation as the core and supported by global operations.Looking ahead, SnowValley will continue to enhance its product R&D capabilities and expand its international presence. By delivering high-quality deep-processed potato products, SnowValley  aims to empower the development of the global foodservice industry, promote the standardization and upgrading of the sector through leading quality, and continuously explore and create sustainable value within the global food supply chain.Company: SnowValley Food Hebei Co.,Ltd.Contact Person: Joyce YangEmail: sales@snowvalleyfood.comWebsite: https://snowvalleyfood.com/en/Telephone: +86 131 6429 9552City: Zhangjiakou, Hebei Province Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK）宣布與北京天廣實生物技術股份有限公司（以下簡稱“天廣實”）達成商業化授權許可合作協議，獲得倍捷欣(R)（MIL62，通用名：奧妥珠單抗β注射液）在亞太地區（東南亞、印度、韓國、澳大利亞、新西蘭、中國香港、中國澳門及中國臺灣地區）的臨床開發及商業化權益。根據相關協議，雲頂新耀將向天廣實支付人民幣2,300萬元的首付款，以及最高不超過人民幣1.86億元的銷售里程碑款。天廣實可獲得該產品在亞太地區的銷售毛利額分成款項。此次合作將進一步強化雲頂新耀在腎科及自身免疫疾病等領域的亞太市場布局，並與現有腎科管線形成協同效應。雲頂新耀將依託已獲驗證的臨床開發及商業化能力，加速推動倍捷欣(R)的市場准入與商業化進程，持續釋放亞太區域的增長潛力，並推進公司在全球創新藥市場的長期戰略發展。倍捷欣(R)是天廣實自主研發的創新型第三代CD20抗體藥物。根據相關資料顯示，該藥物已於2026年2月在中國獲批上市，用於治療視神經脊髓炎譜系疾病（NMOSD），成為全球首款治療該疾病的CD20抗體，也是中國在該領域的首款國產藥物。倍捷欣(R)用於治療原發性膜性腎病（PMN）的新藥上市申請亦處於中國國家藥監局的「優先審評審批」階段，有望成為全球首款獲批的PMN特效藥物。此外，倍捷欣(R)正在進行的臨床III期試驗覆蓋系統性紅斑狼瘡（SLE）以及濾泡性淋巴瘤（FL）多個治療領域，並具備向其他自身免疫性疾病持續拓展的潛力。雲頂新耀董事會主席吳以芳表示：「我們非常高興能與天廣實就倍捷欣(R)達成此次合作。倍捷欣(R)不僅是全球首款獲批治療NMOSD的CD20抗體，也是一款具有差異化優勢和廣闊市場前景的創新藥，在腎科及自身免疫疾病領域展現出顯著的臨床潛力。此次合作將進一步豐富雲頂新耀在腎科及自身免疫領域的產品布局，並與現有管線形成良好的協同效應。依託公司已建立並持續強化的臨床開發及商業化能力，我們有信心加速推進倍捷欣(R)在亞太地區的開發與商業化進程，推動其儘快惠及更多患者，讓創新療法更快轉化為臨床可及性，並進一步提升公司在亞太及全球創新藥市場的影響力。」天廣實總裁陳魯寧表示：「我們非常欣喜與雲頂新耀達成倍捷欣(R)在亞太地區的合作。倍捷欣(R)作為全球首款獲批治療NMOSD的CD20靶向藥物，也是潛在全球首款治療PMN的特效藥物，擁有非常出色的產品競爭力與市場潛力。自產品上市以來，倍捷欣(R)在中國大陸地區已經取得了優異的商業化成績，此次合作將進一步強化倍捷欣(R)在整個亞太市場的商業化網路與品牌影響力，為中國大陸以外的更多腎科及自身免疫性疾病患者帶來「欣」希望。」倍捷欣(R)目前已在腎科及多個自身免疫疾病領域展現出顯著的臨床及治療價值，並具備廣闊的適應症拓展潛力。其在NMOSD、PMN及SLE等疾病領域的持續布局與進展，有望為患者帶來更多創新治療選擇。NMOSD是一種高復發率、高致殘率的中樞神經系統自身免疫性疾病，多發於青壯年女性。該病通常為急性或亞急性起病，可迅速進展，約90%的患者在三年內經歷復發，嚴重者可導致失明甚至癱瘓。倍捷欣(R)在單藥治療中顯示出降低復發風險的顯著優勢，並在療效數據中展現出優異表現，凸顯其作為單藥療法的臨床價值與治療便利性。PMN是成人腎病最常見的病理類型，約30%-40% 的患者在5-15年內可能進展為終末期腎病。目前全球範圍內尚無獲批的特效藥。臨床III期研究顯示，倍捷欣(R)單藥治療在臨床完全緩解、免疫學完全緩解及臨床緩解等各項指標上均展現出顯著優勢。此外，倍捷欣(R)具有良好的安全性和耐受性，並且給藥週期便捷，患者初始治療後，每六個月僅需進行一次靜脈注射，可顯著降低治療負擔，同時有助於提升長期依從性。SLE是一種慢性系統性自身免疫疾病，倍捷欣(R)目前處於臨床III期研究階段，具有24–28周的長給藥間隔優勢，可滿足患者對長效治療方案的臨床需求，有望為SLE患者提供更優治療選擇。此次合作被視為雲頂新耀提升腎科及自身免疫領域戰略縱深的重要舉措。隨著倍捷欣(R)在PMN等適應症上的開發與商業化推進，公司腎科產品矩陣將得到進一步補充，並強化現有管線的協同效應。此外，業內普遍認為，未來數年中國創新藥加速進入亞太市場將迎來重要發展機遇。憑藉臨床價值、可負擔性及可及性方面的綜合優勢，中國創新藥與亞太地區日益增長的醫療需求持續契合。雲頂新耀近年來持續推進亞太區域戰略布局，已逐步形成覆蓋臨床開發、市場准入及商業化運營的能力體系。通過引入倍捷欣(R)等具備差異化臨床價值的創新產品，雲頂新耀正進一步拓展區域產品組合及市場覆蓋，推動公司腎科及自身免疫領域商業化價值的釋放，並為亞太業務發展注入新的增長動能。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 今年，高瓴資本以每股5.8港元、溢價12%的代價一舉拿下現代牙科1.61億股，躍升為第二大股東。市場一度好奇：這究竟是財務投資，還是對全球義齒龍頭價值的重倉押注？帶著這個疑問，我們走進了現代牙科位於東莞松山湖的全球核心生產基地，試圖從產業邏輯出發，梳理2026年公司必須關注的幾大核心亮點。（現代牙科東莞基地調研相關影像資料）數碼化滲透加速，行業拉開結構性重塑大幕全球義齒行業正處於從"手工作坊"向"數碼化智造"轉型的關鍵拐點。當前口內掃描器在牙醫端的普及率僅15%-25%，仍屬早期滲透階段。隨著設備降價和教學體系更新，未來幾年將進入加速普及期。數碼化帶來的變化是顛覆性的：-交付週期從傳統9-11天壓縮到7天以內；-返工率從行業平均6%-8%銳減至1%-2%；-數碼化能力正成為牙醫選擇供應商的首要決策變數。據美國牙科技工所協會數據，美國牙科實驗室65%的銷售來自單人執業的牙醫診所，這些機構普遍缺乏對數碼化轉型的認知。而現代牙科作為全球義齒行業數碼化先鋒，正成為這廣闊市場的革新者，加速市場教育的同時也在不斷提升自身佔有率。行業數碼化轉型大勢所趨，現代牙科將充分受益行業轉型紅利。集中生產+自有分銷，鑄就全球化雙輪驅動壁壘現代牙科的核心競爭模式可概括為"低成本國家集中生產、高附加值市場全球分銷"。公司在東莞、越南、泰國等地建立了多個集中化生產基地，不僅有效分散地緣政治風險，也為未來3-5年儲備了充裕的產能擴張空間。東莞基地2024年完成深圳產能整合，運營效率顯著提升；越南工廠進入成熟期；泰國Hexa Ceram市占率超28%，成為輻射東南亞的重要支點。更關鍵的是，公司通過近十年的並購整合，搭建起覆蓋全球的自有獨家分銷網路。旗下Elysee、Labocast、洋紫荊等本地化品牌，配合集中生產模式，帶來了更高的定價權與客戶粘性，這是許多代工廠難以逾越的護城河。從代工到方案設計，數碼化升維賦能牙醫現代牙科已悄然完成角色躍遷——從被動接單的加工廠，轉型為主動為牙醫賦能的"數碼化解決方案提供商"。通過整合口內掃描、面部掃描、CBCT等多源醫療數據，公司能直接為牙醫輸出治療方案設計、笑容模擬、治療前後對比，從而將自身價值從"產品供應"升級為"診所營收增長的催化劑"。這一能力顯著提升了高單價療程（如種植、貼面、矯正）的轉化率，並深化了牙醫對公司的依賴。同時，基於40年複雜案例資料庫推進的"混合療程+交叉銷售"戰略，將義齒修復與旗下自研透明矯治器TrioClear、牙齒美容貼面等打包為整體笑容設計服務。2025年，TrioClear已實現收益5,970萬港元，兩年複合增長率達33.2%，驗證了品牌力和管道協同效應。門檻抬高、長尾出清，全球複製能力加速收割數碼化義齒製造對資本、設備、軟體、數據處理和技師培訓提出了極高要求，涵蓋口內掃描檔案處理、CAD/CAM、3D打印、三維成像等數碼化技術，實現從數據採集、診斷設計到協助醫生治療實施的全流程數碼化。這正在系統性地擠走缺乏資金和技術的小型技工所，釋放出大量市場份額。現代牙科憑藉規模效應和資金優勢，正被動兼主動收割這些份額。與此同時，公司覆蓋全球的銷售網絡和牙科智庫生態，賦予了其罕見的"從1到100"的複製能力。任何在單一市場驗證成功的創新方案（如TrioClear），均可通過自有管道迅速導入歐美、澳洲、大中華等其他市場。這種全球推廣效率，是區域性廠商根本難以望其項背的。強化醫療數據處理能力，成為AI時代的口腔數據巨頭公司每年處理近300萬宗修復案例，積累的是一份海量、多源、高標注品質的口腔醫療數據資產。在AI大模型重塑各行各業的當下，這一數據金礦的價值愈發凸顯。智能演算法已可輔助牙齒形態設計、自動檢測缺陷，進一步提升效率和一致性；未來，基於真實世界數據的持續學習，更有望不斷孵化出新的治療方案與產品。高瓴入局，強強聯手打開戰略協同新空間高瓴資本的9.35億港元入場絕非簡單的財務投注。其在醫療健康領域的深厚根基，尤其是對時代天使等牙科標杆項目的成功運作，為現代牙科注入了豐富的想像空間：資本上增強並購整合與研發實力；資源上對接頂級的投後管理與行業專家網路；技術上高瓴在AI及大數據領域的投資積累，有望與現代牙科的口腔數據資產形成戰略協同，助攻智能化轉型。這更像是高瓴對"全球牙科數碼化基礎設施"投下的一張長期信任票。2026年的現代牙科，正處在從"義齒代工廠"向"全球牙科數碼化服務平臺"躍遷的關鍵節點。其價值內核已不單是產能規模，更體現在全球自有分銷網路、集中生產與本土品牌協同、數碼化主動設計、海量數據資產、外部戰略協同這五大支柱之上。在行業數碼化加速、小型競爭者出清、全球牙科剛需穩步增長的大背景下，公司有望持續實現收入的高單位數至雙位數增長，並帶動毛利率中樞穩步抬升。來源：港股投研所 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - Managing money in a high-cost city like Singapore can feel complex, especially when multiple financial commitments run in parallel. From education expenses and medical bills to consolidating existing dues, Personal Loans in Singapore are often explored as a flexible financing option. When approached thoughtfully, they can help create breathing room in monthly cash flow and bring more structure to scattered payments. The key lies in understanding how these loans work in the local context and using them in ways that align with income patterns, interest rates, and realistic repayment timelines.Understanding how Personal Loans work in SingaporePersonal Loans in Singapore are unsecured loans, meaning they do not require collateral such as property or fixed deposits. Loan amounts can vary widely depending on income eligibility and lender criteria, subject to applicable regulatory requirements. Interest rates are often quoted as flat rates or effective interest rates (EIR), with EIRs commonly ranging between 2.65% and 3.75% per annum for salaried individuals. Understanding the difference between flat rates and EIRs, as well as how rates vary across lenders, can help borrowers estimate the actual cost of borrowing more accurately. Repayment tenures usually span from one to five years, offering flexibility to match monthly obligations with income cycles.Situations where Personal Loans may help improve cash flowPersonal Loans may be useful in specific scenarios where timing and predictability matter more than long-term borrowing. For instance, consolidating multiple high-interest payments into one structured loan can simplify finances and make monthly outflows easier to track. A consolidated single personal loan instalment per month may feel more manageable than juggling three or four smaller payments with varying due dates. Similarly, planned expenses such as professional certifications or home repairs may benefit from fixed monthly repayments rather than ad-hoc withdrawals from savings. This approach can help maintain liquidity while spreading costs over time.Using Personal Loans for Debt ConsolidationDebt consolidation is one of the more common reasons borrowers explore personal loans in Singapore, especially when dealing with credit card balances. For illustration purpose, credit cards may carry interest rates exceeding 25% per annum, which may strain monthly budgets if balances revolve. A Personal Loan with a materially lower EIR may help reduce the interest burden while providing a clear repayment end date. Over a three-year tenure, consolidating SGD 20,000 in outstanding balances may translate into more predictable instalments and less uncertainty around interest accumulation, depending on the applicable terms. This structured approach may help improve financial clarity without relying on short-term credit cycles.Practical tips to use Personal Loans thoughtfullyAlign the loan amount with a clear purposeBorrowing with a defined goal can help keep loan usage focused and intentional. Whether the aim is consolidating debt or funding a necessary expense, having a specific number in mind can prevent over-borrowing. In Singapore, lenders may offer higher limits based on income, but choosing only what is required can help keep monthly instalments comfortable. This approach may also reduce total interest paid over the loan tenure.Compare EIR, not just headline offersAdvertised rates can sometimes appear attractive, but the EIR provides a clearer picture of the total cost. Processing fees, early repayment charges, and administrative costs can influence the final amount paid. For example, a loan with a 3% flat rate can translate to an EIR closer to 5.5% once fees are factored in. Comparing EIRs across lenders can help identify options that fit better within monthly budgets.Choose a tenure that balances flexibility and affordabilityLonger tenures reduce monthly instalment amounts, but they also increase total interest paid. Shorter tenures may feel heavier on cash flow but can close the loan faster. Borrowers earning between SGD 4,000 and SGD 6,000 per month often opt for a two- to three-year tenure, as it balances instalment size with interest impact. Selecting a tenure that aligns with income stability can help maintain consistency in repayments.Understanding income-based borrowing limitsIn Singapore, borrowing limits for personal loans are typically tied to annual income levels and overall credit assessment. Individuals earning less than SGD 20,000 annually are generally subject to more restrictive unsecured credit caps, while those earning above SGD 30,000 may be eligible for higher unsecured credit limits, subject to the banks' internal credit assessments and applicable regulatory requirements. These guidelines are designed to encourage responsible borrowing without overextending financial capacity. Staying within these limits can help ensure that loan repayments remain proportionate to income, leaving room for savings and everyday expenses. This balance can support longer-term financial resilience rather than short-term relief.Building a healthier money outlook with structured repaymentsOne often overlooked benefit of personal loans is the predictability they bring to monthly planning. Fixed instalments can make it easier to map expenses, set aside savings, and track progress over time. Seeing a loan balance reduce each month steadily may also encourage better financial habits. In Singapore's fast-paced environment, this structure may help individuals stay focused on broader money goals while managing immediate needs. Over time, this clarity may contribute to improved confidence in handling finances.Making Personal Loans work for your financial contextUsing personal loans thoughtfully in Singapore can be a practical way to bring order to complex financial situations. When loan amounts, interest rates, and tenures are aligned with income and clear objectives, they can help improve cash flow and reduce financial stress. Rather than acting as a quick fix, personal loans can serve as a structured tool that supports better financial management. With careful comparison and realistic planning, they may fit into a broader strategy aimed at stability and long-term financial well-being.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB LtdContact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.Travere Therapeutics, is a Nasdaq-listed US biopharmaceutical company (NASDAQ: TVTX) with a focus on the field of rare glomerular diseases, particularly targeting IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company is also developing therapeutic programs for rare genetic metabolic diseases, such as homocystinuria (HCU). Its core product, FILSPARI®(sparsentan) is the first and only medicine approved by the FDA for the treatment of FSGS, further strengthening the company’s leading position in the renal therapy sector.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. As an investigational oral, covalent reversible BTK inhibitor, civorebrutinib is designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney disease. Driven by strong clinical development capabilities, Everest Medicines has recently achieved several key milestones in global multi-center trials, in-house R&D pipeline validation, and international licensing partnerships. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. EVER001 possesses therapeutic development potential in multiple immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. EVER001 is expected to offer a new treatment option for more than 10 million affected patients globally. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. “This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”“Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”This cooperation between Everest Medicines and Travere Therapeutics further propels the globalization of EVER001, reflecting the continued unlocking of the value of Everest Medicines innovative drugs. Currently, Everest Medicines has established a comprehensive renal product matrix inclding Nefecon®, MT1013, and EVER001, spanning indications such as IgA nephropathy, secondary hyperparathyroidism (SHPT), and a wide range of immune-mediated kidney diseases. By continuously deepening its strategic layout in nephrology, Everest Medicines is accelerating its global footprint to provide accessible and reliable treatment solutions for more patients through innovative therapies.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK）宣布與Travere Therapeutics, Inc.（NASDAQ: TVTX，以下簡稱「Travere Therapeutics」）達成獨家授權許可與合作協議。根據協議，Travere Therapeutics將獲得EVER001（希布替尼，civorebrutinib）除大中華區及部分東南亞國家以外區域的獨家開發及商業化權益。此次合作將加EVER001的全球臨床開發與商業化進程，為全球腎病患者帶來創新治療選擇。根據協議，雲頂新耀將獲得1.125億美元的首付款，以及在最多五個適應症上獲得高達10.3億美元的開發、註冊及商業化里程碑付款。此外，基於EVER001的未來年度淨銷售額，雲頂新耀將獲得從高個位數至雙位數百分比的分級特許權使用費。該交易將在滿足特定交割條件及完成必要監管程式後完成交割。本次雲頂新耀的合作方Travere Therapeutics是一家在納斯達克上市（股票代碼：TVTX）的美國生物制藥公司，重點布局罕見腎小球疾病領域，尤其聚焦IgA腎病和局灶節段性腎小球硬化（FSGS），並在研用於同型半胱氨酸尿症（HCU）等罕見遺傳代謝疾病的治療專案。其核心產品FILSPARI®（sparsentan）是一種口服雙重內皮素受體拮抗劑及血管緊張素II AT1受體拮抗劑，已獲美國FDA批准用於治療IgA腎病及FSGS，成為全球首個且唯一獲批用於FSGS治療的藥物，進一步強化其在腎病治療領域的領先地位。EVER001是一款新一代共價可逆布魯頓酪氨酸激酶（BTK）抑制劑，具備「一個可以開發多種適應症的藥物（pipeline-in-a-product）」的開發潛力。與共價不可逆BTK抑制劑相比，EVER001作為一款潛在的同類最佳產品，在保持高活性的同時具有高選擇性，避免持續抑制帶來的毒副作用。近年來，雲頂新耀憑藉強大的臨床開發能力，在全球多中心臨床試驗推進、自主研發管線臨床驗證及國際授權合作等方面取得了多項里程碑進展。在EVER001的臨床開發中，雲頂新耀此前公布用於治療中國原發性膜性腎病（PMN）患者的1b/2a期臨床研究數據顯示，EVER001展現出快速、深度且持久的免疫學和臨床緩解，停藥後仍持續獲益，安全性高，耐受性強。這些結果支持EVER001具有治療以蛋白尿為特徵的自身免疫性腎小球疾病的潛力。EVER001具備在多種免疫介導性腎小球疾病中的開發潛力，包括PMN、IgA腎病、微小病變性腎病（MCD）、FSGS及狼瘡性腎炎等。這類疾病均與異常免疫反應引發的腎小球損傷相關，可導致蛋白尿和腎功能下降，嚴重時甚至可能發展至終末期腎病，需要透析或腎移植治療。EVER001有望為全球逾1000萬名相關患者提供新的治療選擇。據悉，Travere Therapeutics計畫在PMN、免疫介導的FSGS及MCD等適應症中推進EVER001的臨床開發，並有望進一步拓展至更多適應症領域。雲頂新耀董事會主席吳以芳表示：「我們非常高興與Travere Therapeutics達成此次合作。這一合作將加速EVER001的全球開發與商業化進程，進一步釋放其在自身免疫性腎臟疾病領域的臨床潛力與商業價值，為全球患者帶來更多創新治療選擇。作為公司自主研發的潛在同類最佳創新藥物，EVER001已在原發性膜性腎病等自身免疫性腎臟疾病治療中展現出積極潛力。憑藉其差異化作用機制，EVER001具備拓展至多種自身免疫性腎臟疾病的潛力，持續釋放其臨床開發潛力。公司始終堅持『BD合作+自主研發』雙輪驅動戰略，持續推進戰略性業務拓展與自主研發，不斷完善全球研發體系建設，持續提升在全球創新藥領域的綜合競爭力。Travere Therapeutics在美國已有獲批的腎科產品，在腎病藥物開發、註冊及商業化方面積累了豐富經驗與成熟能力。雙方將充分發揮各自優勢，共同推進EVER001在原發性膜性腎病、免疫介導的局灶節段性腎小球硬化及微小病變性腎病上的全球臨床開發，為全球患者帶來更多突破性治療選擇。」Travere Therapeutics總裁兼首席執行官Eric Dube博士表示：「EVER001作為我們罕見腎病領域管線的重要戰略性補充，具有高度協同價值，並有望成為覆蓋多種免疫介導罕見腎病的同類最佳療法。罕見腎病患者目前仍面臨巨大的未滿足臨床需求。我們認為，在IgA腎病和FSGS領域已取得的階段性進展，僅是這一治療領域潛力釋放的開始。Travere Therapeutics持續推動該領域的重要創新與突破，憑藉在罕見腎病領域積累的深厚專業經驗、成熟的研發與商業化能力，以及對患者的持續承諾，我們將不斷推動創新，為患者帶來更多突破性治療選擇。作為一款具有差異化優勢的口服可逆BTK抑制劑，EVER001在原發性膜性腎病中已展現出令人鼓舞的概念驗證數據，其作用機制可覆蓋免疫介導的局灶節段性腎小球硬化、微小病變腎病等更多疾病領域。我們相信，EVER001將為罕見腎病患者帶來更具重要意義的治療突破，進一步推動該領域治療格局的重塑。」此次雲頂新耀與Travere Therapeutics的合作，進一步推動了EVER001的全球化進程，也是雲頂新耀創新藥價值進一步釋放的體現。目前，雲頂新耀已形成由耐賦康®、MT1013及EVER001組成的腎科產品矩陣，覆蓋IgA腎病、繼發性甲狀旁腺功能亢進症（SHPT）及多種免疫介導性腎臟疾病。通過持續深化腎科領域戰略布局，雲頂新耀正加速全球布局，以創新療法為更多患者提供可及、可靠的治療方案。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月3日 - (亞太商訊 via SeaPRwire.com) - 近日，香港科技大學（港科大）與蘇州天瞳威視電子科技股份有限公司（CalmCar）正式簽署戰略合作協議，共同成立港科大物理AI科創中心（以下簡稱「科創中心」）。該中心將聚焦物理 AI 全棧技術突破，面向當前AI對物理世界規律理解不足、推演能力有限、行動決策缺乏可靠支撐等核心瓶頸，構建具備理解、預測、推演與決策能力的新一代物理AI技術底座，支撐自動駕駛、機械人、智能製造等戰略性產業發展，助力香港成為國家物理AI創新的重要戰略支點。多維度研究方向：從芯片到應用的全棧佈局科創中心圍繞物理AI前沿研究方向和核心應用場景，覆蓋芯片與系統、基礎模型與數據、隱私保護與安全治理等，通過探索及利用世界模型構建高保真策略驗證與交互推演能力，讓AI能夠在虛擬環境中進行推演和學習，再將能力遷移到真實世界，從而顯著提升AI在複雜開放環境中的泛化性、可解釋性與系統可靠性，為廣泛的智能應用構建長期技術底座。中心的目標打造全球物理AI創新戰略樞紐，主導領域評測基準與開源平台，培養具有國際競爭力的物理AI人才。立足香港、服務國家「AI+」戰略科創中心將積極服務國家「AI+」戰略，以香港為立足點、粵港澳大灣區為腹地、全球為舞台，致力於成為亞太地區物理智能研究的戰略高地與國際合作樞紐。中心將構建從基礎研究到產業落地的端到端研究能力，為行業提供統一的技術標準和通用工具。同時，中心將依託香港的國際化優勢和大灣區完備的產業鏈資源，加速科技成果轉化，打造世界一流的物理智能研究創新中心。頂尖學術班底，築牢科研基石科創中心由加拿大工程院院士、歐洲科學院外籍院士、IEEE Fellow、港科大計算機科學及工程學系講座教授郭嵩教授出任主任，牽頭主持各項工作。郭嵩教授長期深耕分佈式計算、邊緣AI及多模態大模型領域，致力於攻克AI在真實物理環境中的泛化性與可靠性難題，曾獲計算機領域最高學術成就之一的IEEE Edward J. McCluskey技術成就獎，是該領域的國際領軍學者。其領銜的普適智能實驗室是扎根香港十年，已在物理世界建模、具身強化學習、邊緣智能系統優化等領域積累了大量原創性成果，為科創中心的技術攻關奠定了堅實的理論根基。 郭嵩教授指出：「我們首創的『物理對齊』技術，將生成式視頻模型升級為可交互的世界模型，標誌着AI從『看世界』邁向『動手改變世界』的新階段。通過虛擬空間無限試錯，我們為下一代自動駕駛的行為預測與安全規劃提供了全新範式。」 鄭緯民先生在致辭中定調：物理AI將是繼通用大模型之後的重要戰略方向。隨後，他主持了戰略諮詢委員會與科創中心的握手合影儀式，標誌着該領域正式邁入產學研融合新階段，寄望物理AI科創中心能夠持續為國家人工智能戰略貢獻重要力量。科創中心特邀中國工程院資深院士、中國計算機學會第十屆理事長、清華大學鄭緯民教授領銜戰略委员会，中國工程院外籍院士、英國皇家工程院院士、歐洲科學院院士、港科大首席副校長郭毅可教授作為中心的校方顧問，將為科創中心提供堅實支持；戰略委員會其他顧問成員還包括；中國工程院外籍院士、加拿大皇家科學院院士、加拿大工程院院士、滑鐵盧大學沈學民教授；加拿大皇家科學院院士、微軟技术院士、微軟亞洲研究院常務副院長、IEEE Fellow、ACM Fellow郭百寧博士；歐洲科學院院士、IEEE Fellow、ACM Fellow、洛桑聯邦理工學院（EPFL）協理副校長David ATIENZA ALONSO教授。從感知邁向理解，驅動智能系統進化相較於依賴海量數據擬合的傳統AI，物理AI更強調模型對真實世界動態規律與因果結構的理解。物理AI的發展，正推動智能系統從單純的感知識別，向融合物理一致性的動態預測、交互推理與自主決策演進。世界模型作為實現物理AI的重要技術路徑之一，通過構建環境的內部表徵並進行前瞻性推演，為複雜場景中的策略學習與驗證提供了仿真基礎，有望增強系統在分布式場景中的泛化能力與行為可靠性。依託該物理AI科創中心，共同發起方天瞳威視將率先在智能駕駛領域應用相關技術展開實踐，讓智駕系統不僅能看見環境，更能理解物理因果，對交通場景的演化趨勢進行想像，從而實現從感知向認知的持續演進。面向未來，科創中心將致力於與更多產業合作夥伴構建合作，在不同應用場景下實踐和驗證物理AI技術理念，推動世界模型的技術路徑創新，促進物理AI關鍵技術與產業生態的持續融合發展。 揭牌儀式：政產學研領袖共同見證本次科創中心揭牌儀式匯聚政界領導、學界權威、產業領軍代表與投資界精英，與港科大校方代表和天瞳威視創始團隊共同出席、攜手揭牌，香港特別行政區立法會（科技創新界）議員邱達根先生、廣州市大灣區辦常務副主任陳旭先生等重磅嘉賓親臨現場，全程見證科創中心揭幕。作為本次科創中心建設的核心戰略合作方，Lion X Ventures全程深度參與中心籌備與生態搭建，依托自身產業資源、跨境布局與資本優勢，為中心落地營運提供全方位支撐，築牢長遠發展根基。高規格的政產學研陣容，疊加頭部投資機構的戰略賦能，充分彰顯科創中心起步的行業高度、資源厚度與戰略價值，亦標誌着以港科大物理AI技術引領、多方協同聯動的創新產業生態體系，在大灣區正式啟航、全新啟程。港科大-天瞳威視「物理AI科創中心」正式揭牌（從左至右依次為：HSBC香港區行政總裁伍楊玉如女士，香港特別行政區立法會（科技創新界）議員邱達根先生，港科大校董會成員、評議會主席、Madhead行政總裁曾建中先生，港科大電腦科學及工程學系主任周曉方教授，中國工程院院士、中國電腦學會前理事長、清華大學教授鄭緯民教授，天瞳威視董事長兼CEO王曦先生，港科大首席副校長郭毅可教授，港科大副校長（研究及發展）鄭光廷教授，港科大電腦科學及工程學系講座教授、物理AI科創中心主任郭嵩教授，廣州市大灣區辦常務副主任陳旭先生，OCBC中層資本及股權投資部全球主管關昭博先生，Lion X Ventures CEO郭燕妮女士） 鄭光廷校長致辭：「物理智能將是未來十年重塑人類社會的核心力量。我們選擇在這個時刻全力投入這個方向，不只是為了建立一個好的研究組織，而是以我們的視角定義一個新科研領域。我相信，多年後回望今天，這將是科大歷史上一個重要的時刻。」學術界、產業界、投資界多方力量匯聚一堂，充分體現了此次合作的高度與影響力。科創中心的成立不僅是校企合作的里程碑，也成為滬港兩地科技交流創新的典範。「產研聯盟」亮燈現場 「資本聯盟」亮燈現場活動現場同時啟動了「產研聯盟」與「資本聯盟」，香港科技大學、天瞳威視以及其他頭部機構共同發起了兩個聯盟。第一批產研夥伴包括：清華大學、微軟亞洲研究院、51視界（6651.HK）、沐曦股份（688802.SH）、安謀科技、輝羲智能，本次參與的投資機構有：匯豐（0005.HK）、Lion X Ventures、龍石資本、GPTX簡坤資本、德聯資本、G70環球家族辦公室、微木控股、達武創投，这標誌著圍繞物理AI的產學研用協同創新生態正式啟航。產研聯盟將聚焦技術攻關與場景落地，資本聯盟則為領先的技術成果提供資金支持和商業化路徑。在人才培養層面，雙方將共建接軌國際標準的產業實訓體系，由天瞳威視提供真實工程場景與產業化實訓機會，推動形成從基礎研究、技術開發到場景應用的完整生態鏈所需人才的培養體系。本次港科大物理AI科創中心的成立，將進一步在全球最前沿的物理AI領域推動香港與內地的科技交流與資源整合，聯合吸引產業鏈上下游夥伴，打造開放共贏的物理AI產業新格局。關於香港科技大學香港科技大學（港科大）（https://www.hkust.edu.hk/）是國際知名的大學，致力推動創新教學、卓越研究及具影響力的知識轉移。港科大着重為學生提供全面及跨學科的教學，於《2026年 QS 亞洲大學排名》中排行第六，《泰晤士高等教育全球年輕大學排名榜2024》中排行第三，並在《泰晤士高等教育大學影響力排名2025》中全球排第19、全港第一。港科大共有11個學科入選《2026年QS世界大學學科排名》全球50強；此外，在《泰晤士高等教育世界大學學科排名2026》中，涵蓋人工智能及機器學習的「計算機科學」領域連續十年蟬聯全港第一。此外，港科大在全球大學就業能力排名中，一直位處全球首30名以內，反映畢業生極具競爭力。在研究及創業創新方面，逾八成的科大研究，於香港的大學教育資助委員會最新的「2020研究評審工作」被評為「國際卓越」或「世界領先」水平。截至2026年5月，港科大成員共創立了逾1,900間至今活躍的初創公司，當中包括11間獨角獸企業和22間成功退場的公司（上市集資或被併購）。關於天瞳威視蘇州天瞳威視電子科技股份有限公司（CalmCar）成立於2016年，是中國領先的以軟件為核心的L2-L2+級及L4級駕駛解決方案提供商。按2024年裝機量計，公司位居中國第二大同時提供行車與泊車解決方案的軟件核心供應商，並率先在海外市場實現L2-L2+級量產方案交付。公司專注於智能駕駛關鍵技術，產品涵蓋行車、泊車、整合駕駛員監測系統的智能座艙解決方案，以及Robobus、Robotruck、Robotaxi及Robosweeper等L4級應用場景，已與超過30 家整車廠展開合作，其中包括2024年中國銷量前十強車企中的9家。戰略投資者涵蓋采埃孚、上汽北美、上汽恒旭、北汽產投、中國聯通、地平線、千方科技、商湯科技、Lion X Ventures、華僑銀行等頭部產業資本，為技術創新與全球化拓展提供堅實支撐。關於Lion X VenturesLion X Ventures是一家立足產業、深耕跨境佈局的專業風險投資機構，聚焦東南亞數字經濟與高端製造賽道，緊抓中國企業出海東南亞的核心趨勢，為高潛力早期及成長階段企業提供資本、產業資源與全球化落地支持。Lion X Ventures隸屬的獅城資本成立於2019年，是專注成長型創新企業的價值型投資機構，亦是數字經濟與產業生態聯合投資的實踐者。機構長期聚焦新一代資訊科技、產業數位化、消費科技、先進製造，同時積極布局綠色科技與碳中和賽道。依托東南亞頂級金融集團資源，採用產業龍頭聯合管理基金模式開展投資，以深度產業視角賦能被投企業，構建中國—東南亞雙向聯動的產業生態，實現資本、產業與區域發展的多方共贏。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 3, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong University of Science and Technology (HKUST) and Suzhou Calmcar Electronics Technology Co., Limited (CalmCar) yesterday officially signed a strategic agreement to jointly establish the Physical AI Innovation Center. The Center is dedicated to advancing full-stack physical AI technologies, addressing fundamental bottlenecks in current AI, including an insufficient understanding of the laws of the physical world, limited reasoning capabilities, and a lack of reliable support for action and decision-making.The Center will build a new-generation physical AI technology foundation capable of understanding, predicting, reasoning, and decision-making, supporting strategic industries such as autonomous driving, robotics, and smart manufacturing, while helping position Hong Kong as a key strategic hub for national physical AI innovation.Multidimensional Research Directions: Full-Stack Layout from Chips to ApplicationsThe Center will pursue research covering chips and systems, foundational models and data, privacy protection and safety governance, as well as core application scenarios. By exploring and leveraging world models to build high-fidelity strategy validation and interactive reasoning capabilities, the Center aims to train AI in virtual environments before transferring capabilities to the real world-significantly improving AI‘s generalizability, interpretability, and reliability in complex and open environments, and building a long-term technical foundation for a wide range of intelligent applications.The Center’s ambition is to become a global strategic hub for physical AI innovation, leading the development of industry benchmarks and open-source platforms, and cultivating internationally competitive talent in physical AI.Based in Hong Kong, Serving the National “AI+” StrategyThe Center will actively serve the national “AI+” strategy, positioning itself with Hong Kong as its base, the Greater Bay Area as its hinterland, and the world as its stage. It strives to become a strategic highland for physical AI research in the Asia-Pacific region and an international hub for collaboration. The Center will establish end-to-end capabilities from fundamental research to industrial deployment, providing unified technical standards and common tools for the industry. Leveraging Hong Kong’s global connectivity and the Greater Bay Area’s comprehensive industrial supply chain, the Center will accelerate technology transfer and build a world-leading research and innovation center for physical intelligence.World-Class Academic LeadershipThe Center is led by Prof. GUO Song – Fellow of the Canadian Academy of Engineering, Foreign Member of the European Academy of Sciences (EU), IEEE Fellow, and Chair Professor in the Department of Computer Science and Engineering at HKUST – who serves as its director. Prof. Guo has long been engaged in distributed computing, edge AI, and multi-modal foundation models, dedicated to solving the challenges of generalization and reliability of AI in real-world physical environments.He is a recipient of the IEEE Edward J. McCluskey Technical Achievement Award, one of the highest honors in computer engineering, and is widely recognized as an international leader in the field. He also leads the Pervasive Intelligence Laboratory (PeiLAB), which has been based in Hong Kong for a decade and has produced substantial original achievements in physical world modeling, embodied reinforcement learning, and edge intelligent systems, providing a solid theoretical foundation for the Center’s research endeavors. Prof. Guo Song remarked: “Our pioneering ‘Physical Alignment’ technology upgrades generative video models into interactive world models, marking a shift in AI from ‘seeing the world’ to ‘acting on the world.’ By enabling infinite trial and error in virtual spaces, we provide a new paradigm for behavior prediction and safety planning in next-generation autonomous driving.” Prof. Zheng Weimin stated that physical AI will be a major strategic direction following general-purpose foundation models. He then presided over the handshake and group photo ceremony between the Strategic Advisory Committee and the Innovation Center, marking the field’s official entry into a new phase of industry-academia-research integration. He expressed hope that the Center will continue to make significant contribution to the national AI strategy.The Center has invited Prof. ZHENG Weimin—Senior Member of the Chinese Academy of Engineering, 10th President of the China Computer Federation (CCF), and Professor at Tsinghua University—to chair its Strategic Committee. Prof. GUO Yike—Foreign Member of the Chinese Academy of Engineering, Fellow of the Royal Academy of Engineering (UK) and the European Academy of Sciences (EU), and Provost of HKUST—serves as the University Advisor to the Center, providing strong support.Other Strategic Committee advisors include Prof. Xuemin (Sherman) SHEN—Foreign Member of the Chinese Academy of Engineering, Fellow of the Royal Society of Canada, Fellow of the Canadian Academy of Engineering, and Professor at the University of Waterloo; Dr. Bai-ning GUO—Fellow of the Royal Society of Canada, Microsoft Technical Fellow, Managing Deputy Director of Microsoft Research Asia, IEEE Fellow, and ACM Fellow; and Prof. David Atienza ALONSO — Fellow of the European Academy of Sciences, IEEE Fellow, ACM Fellow, Professor of Electrical and Computer Engineering at EPFL, and Associate Vice President for Centers and Platforms at EPFL.From Perception to Understanding: Driving the Evolution of Intelligent SystemsUnlike traditional AI that relies on massive data fitting, physical AI emphasizes a model’s ability to understand dynamic real-world laws and causal structures. Physical AI is driving intelligent systems beyond perception and recognition toward dynamic prediction, interactive reasoning, and autonomous decision-making grounded in physical consistency. As a key enabling technology, world models simulate and anticipate environmental dynamics, providing a foundation for policy learning and validation in complex scenarios while enhancing generalization and reliability in distributed settings.Leveraging the Physical AI Innovation Center, CalmCar—as a co-founder of the Center— will take the lead in applying these technologies to autonomous driving, enabling vehicles not only to perceive their surroundings but also to understand physical causality and anticipate the evolution of traffic scenarios, thereby advancing from perception to cognition.Looking ahead, the Center is committed to building partnerships with a broader range of industry partners, validating and refining physical AI technologies across diverse application scenarios, driving innovation in world model methodologies, and fostering the sustainable integration of physical AI technologies with the industrial ecosystem.Unveiling Ceremony: Witnessed by Leaders from Government, Academia, and IndustryThe unveiling ceremony brought together government leaders, leading academics, industry executives, and investment professionals. Representatives from HKUST and CalmCar’s founding team jointly unveiled the Center. Distinguished guests, including Mr. Duncan CHIU, Legislative Council Member (Technology & Innovation) of Hong Kong, and Mr. CHEN Xu, Executive Deputy Director of the Guangzhou Greater Bay Area Office, witnessed the launch of the initiative.As a core strategic partner in establishing the Center, Lion X Ventures has been deeply involved in its preparation and ecosystem building throughout the process. Leveraging its industry resources, cross-border reach, and capital expertise, Lion X Ventures provides comprehensive support for the Center’s operations and development, laying a solid foundation for its long-term growth.The high-caliber presence of leaders from government, academia, industry, and investment community, combined with the strategic support of top investment institutions, fully demonstrates the Center’s industry standing, resource depth, and strategic value. It also marks the official launch of a collaborative innovation ecosystem in the Greater Bay Area led by HKUST’s physical AI technologies. The HKUST-CalmCar Physical AI Innovation Center inauguration ceremony(From left to right: Ms. Diana WU, CEO of HSBC Hong Kong; Mr. Duncan CHIU, Legislative Council Member (Technology & Innovation) of Hong Kong; Mr. Terry TSANG, HKUST Court Member and Chairman of the Convocation, CEO of Madhead; Prof. ZHOU Xiaofang, Head of the Department of Computer Science and Engineering at HKUST; Prof. ZHENG Weimin, Academician of the Chinese Academy of Engineering, former Chairman of the China Computer Federation, Professor at Tsinghua University; Mr. WANG Xi, Chairman and CEO of CalmCar; Prof. Guo Yike, Provost of HKUST; Prof. Tim CHENG, Vice-President for Research and Development of HKUST; Prof. Guo Song, Chair Professor of the Department of Computer Science and Engineering at HKUST and Director of the Physical AI Innovation Center; Mr. CHEN Xu, Executive Deputy Director of the Guangzhou Greater Bay Area Office; Mr. Daniel KWAN, Global Head of Mid-Capital and Equity Investment at OCBC; Ms. GUO Yanni, CEO of Lion X Ventures) Prof. Tim Cheng stated: “Physical intelligence will be a core force reshaping human society over the next decade. We have chosen this moment to fully commit to this direction—not merely to build a strong research organization, but to define a new research field from our own perspective. I believe that, years from now, when we look back on today, this will be remembered as an important moment in HKUST’s history.”The gathering of leaders from academia, industry, and investment underscores the significance and impact of this collaboration. The establishment of the Center is not only a milestone in university-industry collaboration but also a model for technology exchange and innovation between Shanghai and Hong Kong. The launch ceremony of the Industry-Research Alliance The launch ceremony of the Capital AllianceThe ceremony also marked the launch of the Industry-Research Alliance and the Capital Alliance, jointly initiated by HKUST, CalmCar, and other leading institutions. The inaugural industry partners include Tsinghua University, Microsoft Research Asia, 51WORLD (6651.HK), MetaX Integrated Circuits (688802.SH), Arm China, and Huixi Technology. Participating investment institutions include HSBC (0005.HK), Lion X Ventures, Dragonstone Capital, GPTX Investment, Delian Capital, G70 MFO, WeMove Capital, and Great Filter Venture.This marks the official launch of a collaborative innovation ecosystem spanning industry, academia, research, and application in the field of physical AI.The Industry-Research Alliance will focus on technology breakthroughs and scenario deployment, while the Capital Alliance will provide funding and commercialization pathways for leading technologies. In terms of talent development, both sides will build an industrial training system aligned with international standards, with CalmCar providing real-world engineering scenarios and hands-on opportunities, thereby nurturing a talent pipeline that spans basic research, technology development, and application deployment.The establishment of the Physical AI Innovation Center will further promote technology exchange and resource integration between Hong Kong and the Chinese Mainland in the most advanced frontier of physical AI. It aims to attract partners across the entire industrial chain and create an open, win-win ecosystem for the physical AI industry.About The Hong Kong University of Science and TechnologyThe Hong Kong University of Science and Technology (HKUST) (https://www.hkust.edu.hk/) is a world-class university known for its innovative education, research excellence, and impactful knowledge transfer. With a holistic and interdisciplinary pedagogy approach, HKUST was ranked 6th in the QS Asia University Rankings 2026, 3rd in the Times Higher Education’s Young University Rankings 2024, and 19th globally and 1st in Hong Kong in the Times Higher Education’s Impact Rankings 2025. Eleven HKUST subjects were ranked among the world’s top 50 in the QS World University Rankings by Subject 2026. In addition, in the Times Higher Education World University Rankings by Subject 2026, HKUST’s Computer Science discipline which encompasses areas such as artificial intelligence and machine learning, has been ranked No. 1 in Hong Kong for ten consecutive years. Our graduates are highly competitive, consistently ranking among the world’s top 30 most sought-after employees. In terms of research and entrepreneurship, over 80% of our work was rated “internationally excellent” or “world leading” in the Research Assessment Exercise 2020 of the Hong Kong’s University Grants Committee. As of May 2026, HKUST members have founded over 1,900 active start-ups, including 11 Unicorns and 22 exits (IPO or M&A).About CalmCarSuzhou Calmcar Electronics Technology Co., Limited (CalmCar) was founded in 2016 and is a leading software-focused provider of L2-L2+ and L4 driving solutions in China. By 2024 installation volume, it ranks as the country’s second largest software-focused provider that offers both driving and parking solutions, and the first Chinese provider to deliver mass-production L2-L2+ solutions overseas. The company focuses on key autonomous driving technologies, offering driving, parking, and intelligent cockpit solutions with integrated driver monitoring systems (DMS), as well as L4 applications including robobuses, robotrucks, robotaxis, and robosweepers. CalmCar has partnered with over 30 vehicle manufacturers, including nine of China’s top ten automakers by sales in 2024. Its strategic investors include ZF, SAIC North America, SAIC Hengxu, BAIC Capital, China Unicom, Horizon Robotics, China TransInfo, SenseTime, Lion X Ventures, OCBC, and other leading industry players, providing solid support for innovation and global expansion.About Lion X VenturesLion X Ventures is a professional venture capital institution rooted in industry and focused on cross-border investment. It targets Southeast Asia’s digital economy and high-end manufacturing sectors. Riding on the trend of Chinese enterprises expanding into Southeast Asia, we deliver capital support, industrial resources and global landing solutions for high-potential startups and growth-stage companies.Founded in 2019, Lion Partners is the parent entity of Lion X Ventures. As a value investor dedicated to growth-oriented innovative enterprises, it is also a pioneer in joint investment across the digital economy and industrial ecosystem. We maintain a long-term focus on next-generation information technology, industrial digitalization, consumer tech and advanced manufacturing, while actively expanding our footprint in green technology and carbon neutrality.Backed by resources from leading financial groups in Southeast Asia, we adopt a co-management fund model partnered with industry leaders. With profound industrial insights, we empower portfolio companies and build a two-way interactive industrial ecosystem connecting China and Southeast Asia, ultimately achieving win-win outcomes for capital, industries and regional development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OTTAWA, ON, June 3, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has executed a non-repayable Contribution Agreement (the "Agreement") with Natural Resources Canada ("NRCan") under the Government of Canada's newly established First and Last Mile Fund ("FLMF"), formerly the Critical Minerals Infrastructure Fund, securing up to $1,378,700 in non-dilutive federal funding (the "Funding") to advance critical transportation and energy infrastructure planning under the Project Titled Lac Knife Graphite Mine Access Road and Hydro Connection (the "Project") for the Company's flagship Lac Knife Graphite Project ("Lac Knife") in northeastern Quebec.The Funding will support engineering, environmental, permitting, community engagement and feasibility activities required to advance the planned all-season access road and Hydro-Quebec grid connection toward a construction-ready, shovel-ready stage. Once completed, these pre-development activities are expected to materially de-risk future infrastructure development and significantly advance Lac Knife's pathway toward future construction, development financing, strategic partnerships and operation.The Funding forms part of the Government of Canada's recently announced C$3.6 billion Critical Minerals Investment Package, unveiled at the 2026 Prospectors & Developers Association of Canada (PDAC) Convention by the Honourable Tim Hodgson, Minister of Energy and Natural Resources. A cornerstone of the package is the C$1.5 billion FLMF, established to advance enabling infrastructure that moves strategic critical mineral projects toward construction readiness while strengthening domestic supply chains and supporting Canada's economic, defence and national security objectives."We are honoured to receive this support from the Government of Canada, which recognizes the strategic importance of the Lac Knife project to the North American critical minerals supply chain," said Dean Hanisch, Chief Executive Officer of Focus Graphite. "As we advance toward permitting and development, this funding is a strong endorsement of Focus Graphite's role in helping build a secure domestic supply of high-grade graphite. We are also fortunate to have existing road and power infrastructure, providing a significant advantage as we move closer to production."Lac Knife hosts one of North America's highest-grade natural graphite deposits and represents a strategically important source of natural graphite for North American and allied supply chains. Natural graphite is a foundational material for lithium-ion batteries, advanced manufacturing, energy storage systems, and a growing range of defence and dual-use technologies, making secure domestic supply increasingly important to Canada and its allies."The objective is simple: advance Lac Knife, reduce risk and preserve shareholder capital," said Jason Latkowcer, Vice President of Corporate Development of Focus Graphite. "Around the world, governments and industry are moving quickly to secure critical mineral supply chains. We've heard that message directly from allies and strategic stakeholders. There isn't time to waste. This funding helps move Lac Knife from planning toward execution. Early technical work has already identified opportunities to improve access, and we expect further optimization as engineering and infrastructure planning advances. This is another tangible step toward building a strategic graphite asset for Canada and its allies."A key component of the program includes collaboration with Indigenous communities, including the Innu Takuaikan Uashat mak Mani-Utenam ("ITUM"). The Project includes the establishment of joint technical and steering committees, Indigenous workforce participation initiatives, skills development programs, community consultation activities and support for Indigenous participation in the future development and operation of the planned infrastructure. These activities align with the objectives of the First and Last Mile Fund to advance Indigenous leadership, engagement and participation throughout the development of strategic critical mineral infrastructure."The development of Lac Knife is a perfect example of Canada's new mining era: a strategic project, developed to benefit local economies, sustainably, and in partnership with Indigenous Peoples, along with advancing Canada's role as a reliable global supplier of critical minerals," said the Honourable Tim Hodgson, Minister of Energy and Natural Resources. "By investing in the infrastructure and early work needed to advance this high-grade graphite project, we are reducing risk, accelerating development, and helping to build a secure, end-to-end supply chain-from mine to market. This is how we strengthen economic and supply chain security for decades to come."The infrastructure initiative is expected to deliver multiple long-term benefits to Canada and Quebec. The proposed access road will establish reliable year-round access to the Lac Knife site, while the future transmission connection will support the electrification of mining operations through Quebec's hydroelectric grid, reducing reliance on diesel-powered infrastructure and strengthening the sustainability, resilience and security of Canada's critical minerals supply chain. The planned infrastructure is expected to support future production, improve regional access and contribute to long-term economic development opportunities across Quebec's North Shore region.Federal Funding DetailsUnder the executed Agreement, NRCan will provide up to C$1,378,700 in non-repayable funding, representing approximately 50% of total eligible Project costs. Focus Graphite will contribute an equivalent amount toward the Project. The Agreement represents another important step in advancing Lac Knife and reinforces Canada's commitment to developing secure domestic critical mineral supply chains from extraction through processing and delivery into North American and allied markets.Funding will support the full work program outlined in the Agreement, including feasibility and engineering studies, environmental baseline work, geotechnical and LiDAR surveys, stakeholder engagement, regulatory and permitting activities and detailed infrastructure design. These activities are expected to culminate in finalized engineering plans, environmental assessments, community approvals and permit applications required to support future construction decisions.The Project is scheduled to continue through March 2028.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures an eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comLinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things: the anticipated receipt and use of funding under the Contribution Agreement with Natural Resources Canada; the completion of the activities contemplated under the Lac Knife Graphite Mine Access Road and Hydro Connection Project; the advancement of the Lac Knife Graphite Project toward construction-ready and shovel-ready status; the completion of engineering, environmental, permitting, stakeholder engagement and feasibility activities; the anticipated benefits of the planned access road and Hydro-Québec grid connection; the Company's ability to secure required approvals, permits and community support; the timing and completion of the Project work program; the potential for future development financing, government funding, strategic partnerships and offtake arrangements; the future development, construction and operation of the Lac Knife Project; the role of Lac Knife in supporting domestic and allied critical mineral supply chains; and the Company's ability to pursue additional non-dilutive funding opportunities and execute its long-term development strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299885 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

阿斯塔納，哈薩克斯坦，2026年6月2日 - (亞太商訊 via SeaPRwire.com) - 由香港特別行政區行政長官李家超率領、香港貿易發展局（香港貿發局）組織的商貿代表團，於6月1日起訪問哈薩克斯坦首都阿斯塔納，期間共促成43份備忘錄及合作協議，涵蓋經貿、投資、金融服務、科技、航空、綠色金融等領域，進一步深化香港、內地與哈薩克斯坦在經貿及產業層面的合作關係，充分發揮香港作為國家雙向服務平台的獨特角色，協助企業開拓中亞市場。代表團明日將完成哈薩克斯坦的行程並啟程前往烏茲別克斯坦，進一步探討香港、內地與中亞國家在共建「一帶一路」框架下的商貿合作。為促進商貿合作，香港特區政府與香港貿發局今日合辦商務午宴，吸引超過300名商界領袖及主要官員出席。香港特別行政區行政長官李家超在商務午宴上表示：「哈薩克斯坦數百年來一直連接東西方文明，擔當商貿、文化和創新思想的橋樑。這一傳統延續至今。從霍爾果斯口岸到跨里海國際運輸通道，哈薩克斯坦現已成為連接我們的國家以及歐洲的商貿和物流樞紐。哈薩克斯坦擁有豐富的石油和礦產資源，正迅速發展和多元化，成為區域經濟強國。香港作為『一帶一路』倡議的重要參與者，期待與哈薩克斯坦攜手合作，創造互惠互利的機遇。」香港貿發局主席馬時亨教授表示：「哈薩克斯坦是中亞最大經濟體，2025年佔區域GDP53%，該國2050策略重點推動經濟多元化，目標到2050年躋身全球最發達的30個國家之列，發展潛力優厚。是次中亞之行令當地企業更了解香港『超級聯繫人』及『超級增值人』的優勢，相信在共建『一帶一路』框架下將迎來多方面的實質合作及機遇，包括物流基建、綠色金融，數字經濟、農業升級及食品加工發展等。『香港基地及貿發局平台＋內地企業出海』的模式，將成為未來中亞合作的新機遇。」繼去年訪問卡塔爾及科威特後，是次代表團再度匯聚香港及內地企業力量。代表團由70位來自香港及內地的商界領袖組成，內地企業代表來自17個省市，涵蓋金融及專業服務、物流運輸、創新科技、貿易、綠色產業、能源及礦業、生物醫藥、汽車產業，以至傳媒等多個界別，共同把握「一帶一路」共建機遇。本次外訪首次邀請新聞行業協會代表隨團，包括香港報業公會及香港新聞行政人員協會，以呼應《施政報告》提出協助本地傳媒發展海外網絡、說好「香港故事」。代表團與哈薩克斯坦多個政府機構、商會及公司高層要員會面，包括哈薩克國家企業家協會（阿塔梅肯）(National Chamber of Entrepreneurs of the Republic of Kazakhstan 'Atameken') 、拜特雷克國家投資控股公司 ('Baiterek' National Investment Holding)、哈薩克人民儲蓄銀行 (Halyk Bank) ，以及薩姆魯克-卡澤納投資公司 (Samruk-Kazyna) ，就促進雙邊經貿往來及產業對接深入交流，並探討以香港作為平台拓展更廣泛區域合作的機遇。代表團亦參觀了阿斯塔納國際科技園 (Astana Hub) 及阿斯塔納國際金融中心 (Astana International Financial Centre) ，深入了解當地在創科及金融領域的最新發展。數據顯示，哈薩克斯坦2026年GDP增長預測4.6%，經濟規模約3,605億美元，繼續穩居中亞最大經濟體及全球前50大經濟體之列。烏茲別克斯坦2026年GDP增長預測6.5%，經濟規模約1,815億美元，在2017至2025年間，該國的GDP按美元計翻倍。整體而言，IMF預測中亞及高加索地區2025年GDP增長6.2%，2026年4.8%（高於全球平均3.1%）。代表團在哈薩克斯坦期間共促成43份備忘錄及合作協議：1香港貿易發展局與哈薩克國家企業家協會（阿塔梅肯）2香港貿易發展局與阿斯塔納國際金融中心3香港貿易發展局與哈薩克國立科技大學4香港機場管理局與阿拉木圖國際機場5一帶一路總商會與哈薩克國家企業家協會（阿塔梅肯）6一帶一路總商會與大宗港聯數字交易股份有限公司與Eurasian Trading System Export” International Commodity Exchange (ETSE)7一帶一路總商會與 JINGSH CONSULTING LLP8香港中華廠商聯合會與哈薩克國家企業家協會（阿塔梅肯）9數碼港與阿斯塔納國際科技園10香港工業總會與哈薩克斯坦人工智能與數字發展部11香港交易及結算所有限公司與Astana International Exchange (AIX)12香港交易及結算所有限公司與阿斯塔納國際金融中心13香港科技園公司與阿斯塔納國際科技園14港深創新及科技園有限公司與阿斯塔納國際科技園15香港總商會與哈薩克國家企業家協會（阿塔梅肯）16香港律師會與哈薩克斯坦國家律師協會17中國銀行(香港)有限公司與哈薩克中國銀行與拜特雷克國家投資控股公司18中國銀行(香港)有限公司與哈薩克中國銀行與薩姆魯克-卡澤納投資公司19博時基金（國際）有限公司與哈薩克人民儲蓄銀行20國泰航空與阿拉木圖國際機場與阿拉木圖政府（旅遊發展部）21中國國際金融股份有限公司與自由控股公司22中國國際金融股份有限公司與薩姆魯克-卡澤納投資公司23中國國際金融股份有限公司與阿斯塔納國際金融中心24中國國際金融股份有限公司與阿斯塔納航空25德勤與寰泰能源股份有限公司26易達資本與Dasco Capital Ltd.27易達資本與阿斯塔納國際金融中心28高鋒集團與Gas Energy Solution LLP29香港新聞行政人員協會與香港報業公會與Khabar Agency JSC30怡和控股有限公司與KIDF31佳鑫國際資源投資有限公司與哈薩克工業和建設部32科能三維技術（醫療）有限公司與哈薩克腫瘤放射研究所33電訊盈科有限公司與Kazakhtelecom34電訊盈科有限公司與Khabar Agency JSC35南華早報與阿斯塔納國際金融中心36南華早報與戈壁創投與阿斯塔納國際科技園與汗騰格裡創新中心37大豆天地農業科技有限公司與哈薩克斯坦國家糧食集團38渣打銀行與哈薩克斯坦開發銀行39善水資本香港有限公司與自由控股公司40英文虎報與Freedom Horizons41渣打銀行與杭州熱聯集團股份有限公司42沃森生物技術股份有限公司與Gold Astrum LLC43易達資本與江蘇關懷醫療科技（集團）有限公司與薩姆魯克-卡澤納投資公司另外，在是此中亞之行期間，亦有非代表團成員就學術、文化等範疇簽署不同備忘錄，包括：甲級能源有限公司與哈薩克斯坦人工智能與數字發展部甲級能源有限公司與自由控股公司中國移動國際有限公司與哈郵圓通香港電訊與香港教育大學香港城市大學與哈薩克斯坦科學與高等教育部下屬國際計劃中心香港城市大學與薩特巴耶夫國立技術大學香港教育大學與納扎爾巴耶夫大學香港理工大學與納扎爾巴耶夫大學香港高等教育科技學院與BILIM-INNOVATION國際社會基金會香港高等教育科技學院與L.N. Gumilyov歐亞國立大學圖片下載：https://bit.ly/49zcFUn代表團於哈薩克斯坦訪問期間促成43份備忘錄及合作協議。為促進商貿合作，香港特區政府與香港貿發局今日合辦商務午宴，吸引當地超過300名商界領袖及主要官員出席。香港特別行政區行政長官李家超在商務午宴上表示：「哈薩克斯坦數百年來一直連接東西方文明，擔當商貿、文化和創新思想的橋樑。這一傳統延續至今。從霍爾果斯口岸到跨里海國際運輸通道，哈薩克斯坦現已成為連接我們的國家以及歐洲的商貿和物流樞紐。哈薩克斯坦擁有豐富的石油和礦產資源，正迅速發展和多元化，成為區域經濟強國。香港作為『一帶一路』倡議的重要參與者，期待與哈薩克斯坦攜手合作，創造互惠互利的機遇。」香港貿發局主席馬時亨教授於午宴上表示：「哈薩克斯坦是中亞最大經濟體，2025年佔區域GDP53%，該國2050策略重點推動經濟多元化，目標到2050年躋身全球最發達的30個國家之列，發展潛力優厚。是次中亞之行令當地企業更了解香港『超級聯繫人』及『超級增值人』的優勢，相信在共建『一帶一路』框架下將迎來多方面的實質合作及機遇，包括物流基建、綠色金融，數字經濟、農業升級及食品加工發展等。『香港基地及貿發局平台＋內地企業出海』的模式，將成為未來中亞合作的新機遇。」代表團參觀阿斯塔納國際科技園 (Astana Hub)，深入了解當地在創科領域的最新發展。傳媒查詢新聞界如有查詢，請聯絡：香港貿易發展局傳訊及公共事務部：徐俊逸電話：(852) 2584 4395電郵：johnny.cy.tsui@hktdc.org張希汶電話：(852) 2584 4272電郵：serena.hm.cheung@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)今年慶祝成立60周年！成立於1966年，香港貿發局是負責促進、協助和發展香港貿易的法定機構。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業（尤其是中小企）開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Astana, Kazakhstan, Jun 2, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), began its visit to Astana, the capital of Kazakhstan, on 1 June. During the visit, a total of 43 memoranda of understanding (MoUs) and announcements were signed, covering areas including trade and commerce, investment, financial services, technology, aviation, and green finance. These agreements further strengthened trade, economic and industrial cooperation among Hong Kong, Chinese Mainland and Kazakhstan, fully leveraging Hong Kong’s unique role as the country’s two-way services platform and supporting enterprises in tapping opportunities in Central Asia.The delegation will conclude its Kazakhstan visit tomorrow and depart for Uzbekistan to further explore business and trade cooperation among Hong Kong, Chinese Mainland and Central Asian countries under the Belt and Road Initiative.To promote business collaboration, the HKSAR Government and the HKTDC jointly hosted a business luncheon today, attracting more than 300 business leaders and senior officials.John Lee, the Chief Executive of the HKSAR, said at the luncheon: “Kazakhstan has, for centuries, connected Eastern and Western civilisations, serving as a bridge of commerce, culture and innovative ideas. That legacy continues today. From the port of Khorgos to the Trans-Caspian International Transport Route, Kazakhstan is now a business and logistics hub linking China, our country, and Europe. Rich in oil and mineral resources, and rapidly developing and diversifying, Kazakhstan is a regional economic powerhouse. Hong Kong, a pivotal player in the Belt and Road Initiative, looks forward to working with Kazakhstan in creating mutual opportunities.”Prof Frederick Ma, Chairman of the HKTDC, said: “Kazakhstan is the largest economy in Central Asia, accounting for 53% of the region’s GDP in 2025. Under its Kazakhstan 2050 Strategy, the country is actively promoting economic diversification, with the goal of becoming one of the world’s top 30 most developed economies by 2050, demonstrating strong growth potential. This visit has enhanced local enterprises’ understanding of Hong Kong’s advantages as a superconnector and super value-adder. Under the Belt and Road Initiative, we believe substantial cooperation opportunities will emerge across various sectors, including logistics infrastructure, green finance, digital economy, agricultural upgrading and food processing. The model of Mainland enterprises going global with Hong Kong while leveraging the HKTDC platform will create new opportunities for collaboration with Central Asia.”Following previous visits to Qatar and Kuwait last year, this delegation once again brings together the strengths of Hong Kong and Mainland enterprises. The delegation comprises 70 business leaders from Hong Kong and enterprise representatives from 17 provinces and municipalities across the Chinese Mainland, covering a wide spectrum of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries, energy and mining, biopharmaceuticals, the automotive industry as well as the media. For the first time, representatives from journalism associations, including The Newspaper Society of Hong Kong and the Hong Kong News Executives’ Association, have joined the delegation, in line with the Policy Address’s initiative to enable local media to develop their overseas network and tell the Hong Kong story.During their stay in Kazakhstan, the delegation met with senior representatives from government bodies, chambers of commerce and major corporations, including the National Chamber of Entrepreneurs of the Republic of Kazakhstan ‘Atameken’, ‘Baiterek’ National Investment Holding, Halyk Bank and Samruk-Kazyna. They exchanged views on strengthening bilateral trade ties and industrial collaboration and explored opportunities to leverage Hong Kong as a platform for broader regional cooperation.The delegation also visited Astana Hub and the Astana International Financial Centre (AIFC) to gain insights into the latest developments in innovation and technology as well as financial services in Kazakhstan.According to available data, Kazakhstan’s GDP is projected to grow by 4.6% in 2026, reaching approximately US$360.5 billion, to maintain its position as the largest economy in Central Asia and among the world’s top 50 economies. Uzbekistan’s GDP is forecast to grow by 6.5% in 2026, reaching approximately US$181.5 billion, with its GDP in US dollar terms having doubled between 2017 and 2025. Overall, the IMF forecasts GDP growth for Central Asia and the Caucasus at 6.2% in 2025 and 4.8% in 2026, higher than the global average of 3.1%.  During its Kazakhstan visit, the delegation facilitated 43 MoUs and announcements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Bank of China Kazakhstan and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Goldford Group and Gas Energy Solution LLP29.Hong Kong News executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC30.Jardine Matheson and KIDF31.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan32.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology33.PCCW and Kazakhtelecom34.PCCW and Khabar Agency JSC35.SCMP and Astana International Financial Centre (AIFC)36.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub37.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan38.Standard Chartered Bank and Development Bank of Kazakhstan39.Templewater and Freedom Holdings40.The Standard and Freedom Horizons41.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.42.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC43.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLPIn addition, during the Central Asia visit, non-delegation members also signed a number of MoUs in academic, cultural or other collaboration areas:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.HKT and Education University of Hong Kong5.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan6.City University of Hong Kong and Satbayev University7.Education University of Hong Kong and Nazarbayev University8.Hong Kong Polytechnic University and Nazarbayev University9.Thei and BILIM-INNOVATION International Social Foundation10.Thei and L.N. Gumilyov Eurasian National UniversityPhoto download: https://bit.ly/49zcFUnDuring its visit to Kazakhstan, the delegation facilitated 43 memoranda of understanding (MoUs) and announcementsTo promote business collaboration, the HKSAR Government and the HKTDC jointly hosted a business luncheon, attracting more than 300 local business leaders and senior officials. John Lee, the Chief Executive of the HKSAR, said at the luncheon: “Kazakhstan has, for centuries, connected Eastern and Western civilisations, serving as a bridge of commerce, culture and innovative ideas. That legacy continues today. From the port of Khorgos to the Trans-Caspian International Transport Route, Kazakhstan is now a business and logistics hub linking China, our country, and Europe. Rich in oil and mineral resources, and rapidly developing and diversifying, Kazakhstan is a regional economic powerhouse. Hong Kong, a pivotal player in the Belt and Road Initiative, looks forward to working with Kazakhstan in creating mutual opportunities.”Prof Frederick Ma, Chairman of the HKTDC, said at the luncheon: “Kazakhstan is the largest economy in Central Asia, accounting for 53% of the region’s GDP in 2025. Under its Kazakhstan 2050 Strategy, the country is actively promoting economic diversification, with the goal of becoming one of the world’s top 30 most developed economies by 2050, demonstrating strong growth potential. This visit has enhanced local enterprises’ understanding of Hong Kong’s advantages as a superconnector and super value-adder. Under the Belt and Road Initiative, we believe substantial cooperation opportunities will emerge across various sectors, including logistics infrastructure, green finance, digital economy, agricultural upgrading and food processing. The model of Mainland enterprises going global with Hong Kong while leveraging the HKTDC platform will create new opportunities for collaboration with Central Asia.”The delegation visited Astana Hub to gain insights into the latest developments in the innovation and technology sectorMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgSerena Cheung Tel: (852) 2584 4272  Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

阿斯塔納，哈薩克斯坦, 2026年6月2日 - (亞太商訊 via SeaPRwire.com) - 2026年6月1日，由香港特別行政區行政長官李家超率領、香港貿易發展局（香港貿發局）組織的商貿代表團，今日展開為期五天中亞的行程（6月1日至6月5日）。走訪哈薩克斯坦的阿斯塔納，以及烏茲別克斯坦的塔什干，與當地政府部門、重要金融機構、大型企業及商會高層會面，並舉辦商貿交流宴會，積極發掘投資及合作機會，推廣香港「內聯外通」及最佳「出海」平台的獨特優勢。香港貿發局主席馬時亨教授表示：「地緣政治催化多邊合作，香港『資金避風港』功能及橋樑角色比以往更加關鍵，今次商貿代表團是展現香港橋樑優勢的黃金機會，『將危機化成契機』。是次代表團具有三大突出特點：一是人數及規模為歷來最大、二是參與業界範疇最廣泛；三是首次以如此高規格模式訪問中亞地區，推動『樞紐對樞紐』的合作模式。在行政長官帶領下，我們將重點推廣香港作為『超級聯繫人』及『超級增值人』的獨特角色，展示香港是中亞企業進入粵港澳大灣區及內地市場的首選門戶，同時亦是內地企業以香港為基地及貿發局平台、穩健『出海』開拓中亞市場的最佳平台。」馬時亨教授續指:「今次選擇訪問哈薩克斯坦及烏茲別克斯坦，具有重要策略意義。兩國均為『一帶一路』沿線的重要樞紐，亦是中亞經濟規模最大、改革最積極的國家，正大力推行經濟多元化。香港及內地憑藉過去數十年轉型經驗，可協助兩國由『資源型經濟』邁向『高增值、可持續發展』，創造大量合作和投資機會，涉及投融資、貿易、物流、輕工業、創新科技、綠色發展等範疇，進一步鞏固香港、內地與『一帶一路』沿線國家的緊密連繫，為內地、香港與中亞活力經濟體開創互利共贏的新篇章。」繼去年訪問卡塔爾及科威特後，是次代表團再度匯聚香港及內地企業力量。代表團由70位來自香港及內地的商界領袖組成，內地企業代表來自17個省市，涵蓋金融及專業服務、物流運輸、創新科技、貿易、綠色產業、能源及礦業、生物醫藥、汽車產業，以至傳媒等多個界別，共同把握「一帶一路」共建機遇。為呼應《施政報告》提出協助本地傳媒發展海外網絡、說好「香港故事」，本次外訪首次邀請新聞行業協會代表隨團，包括香港報業公會及香港新聞行政人員協會。期望透過是次機會，協助本地媒體強化海外網絡，並開拓活動策劃、品牌推廣及出版等海外商業市場。是次訪問將聚焦哈薩克斯坦及烏茲別克斯坦的國家發展策略，透過考察、機構參觀、高層會面及大型推廣活動，深入發掘金融、物流、基礎設施、科技及綠色投資等領域的合作機會，期望透過面對面交流，促成更多實質投資與合作項目。中亞地區憑藉豐富天然資源、年輕人口結構、「一帶一路」基建連接及持續經濟多元化改革，仍然是全球新興高潛力區域之一。根據國際貨幣基金組織（IMF）2026年4月最新區域經濟展望，中亞及高加索地區（CCA）2025年實質GDP增長達6.2%（優於預期），2026年雖受全球地緣政治不確定性及中東局勢影響，增長預計放緩至約4.8%，但仍明顯高於全球平均3.1%的水平。其中，哈薩克斯坦及烏茲別克斯坦繼續擔當區域增長的引擎角色。圖片下載：https://bit.ly/49ZSNK8香港特別行政區行政長官李家超率領、香港貿易發展局（香港貿發局）組織的商貿代表團，今日展開為期五天中亞行程（6月1日至6月5日），走訪哈薩克斯坦的阿斯塔納及烏茲別克斯坦的塔什干。香港貿發局主席馬時亨教授與代表團舉行簡介會，為是次訪問揭開序幕。傳媒查詢新聞界如有查詢，請聯絡：香港貿易發展局傳訊及公共事務部：徐俊逸電話：(852) 2584 4395電郵：johnny.cy.tsui@hktdc.org張希汶電話：(852) 2584 4272電郵：serena.hm.cheung@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)今年慶祝成立60周年！成立於1966年，香港貿發局是負責促進、協助和發展香港貿易的法定機構。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業（尤其是中小企）開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com